ZNHIT3

Across TCGA pan-cancer cohorts, ZNHIT3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNHIT3 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNHIT3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNHIT3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where ZNHIT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.428	0.860	.019	30	view →
CCRCC	OS	Tertile	II,III,IV	0.420	0.905	.016	1	view →
LSCC	DFS	Median	All	0.962	0.914	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNHIT3–PDAC (DFS)

Open the PDAC breakdown →